The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Open accessThe DOI matches its Crossref record; 167 of the 167 references it cites were found in a registry or an index.
Abstract
The synaptic vesicle glycoprotein 2 (SV2) family is comprised of three paralogues: SV2A, SV2B, and SV2C. In vertebrates, SV2s are 12-transmembrane proteins present on every secretory vesicle, including synaptic vesicles, and are critical to neurotransmission. Structural and functional studies suggest that SV2 proteins may play several roles to promote proper vesicular function. Among these roles are their potential to stabilize the transmitter content of vesicles, to maintain and orient the releasable pool of vesicles, and to regulate vesicular calcium sensitivity to ensure efficient, coordinated release of the transmitter. The SV2 family is highly relevant to human health in a number of ways. First, SV2A plays a role in neuronal excitability and as such is the specific target for the antiepileptic drug levetiracetam. SV2 proteins also act as the target by which potent neurotoxins, particularly botulinum, gain access to neurons and exert their toxicity. Both SV2B and SV2C are increasingly implicated in diseases such as Alzheimer's disease and Parkinson's disease. Interestingly, despite decades of intensive research, their exact function remains elusive. Thus, SV2 proteins are intriguing in their potentially diverse roles within the presynaptic terminal, and several recent developments have enhanced our understanding and appreciation of the protein family. Here, we review the structure and function of SV2 proteins as well as their relevance to disease and therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SV2A is a core presynaptic regulator that coordinates vesicle priming, calcium dependent release, and neurotransmitter loading to ensure reliable synaptic transmission [184,185,186].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [184]
In the citing paper
“Through these convergent actions, SV2A functions as a molecular scaffold that stabilizes presynaptic terminals while postsynaptic strengthening consolidates [175,184,198].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [184]
In the citing paper
“evidence from structural and functional studies suggests SV2 proteins play multiple roles in the “life cycle” of a synaptic vesicle to promote proper vesicular function”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [46]
Citations
Cites
Finishing the euchromatic sequence of the human genome
International Human Genome Sequencing Consortium (2004) · Nature · doi:10.1038/nature03001 · Cited by 4,971
Zerbino, D. R., Achuthan, P., Akanni, W., Amode, M. R., Barrell, D., Bhai, J., Billis, K., Cummins, C., Gall, A., Girón, C. G., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1098 · Cited by 2,605
Südhof, T. C. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.041002.131412 · Cited by 2,547
Molecular anatomy of a trafficking organelle
Takamori, S., Holt, M., Stenius, K., Lemke, E. A., Grønborg, M., Riedel, D., Urlaub, H., Schenck, S., Brügger, B., Ringler, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.030 · Cited by 2,373
Pao, S. S., Paulsen, I. T., & Saier, M. H. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.1.1-34.1998 · Cited by 2,297
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Protter: interactive protein feature visualization and integration with experimental proteomic data
Omasits, U., Ahrens, C. H., Müller, S., & Wollscheid, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt607 · Cited by 1,347
Neurotransmitter Release: The Last Millisecond in the Life of a Synaptic Vesicle
Südhof, T. C. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.022 · Cited by 1,197
Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment
Bakker, A., Krauss, G. L., Albert, M. S., Speck, C. L., Jones, L. R., Stark, C. E., Yassa, M. A., Bassett, S. S., Shelton, A. L., & Gallagher, M. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.023 · Cited by 908
SV2 Is the Protein Receptor for Botulinum Neurotoxin A
Dong, M., Yeh, F., Tepp, W. H., Dean, C., Johnson, E. A., Janz, R., & Chapman, E. R. (2006) · Science · doi:10.1126/science.1123654 · Cited by 770
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749
Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease
Vossel, K. A., Beagle, A. J., Rabinovici, G. D., Shu, H., Lee, S. E., Naasan, G., Hegde, M., Cornes, S. B., Henry, M. L., Nelson, A. B., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.136 · Cited by 741
Release of secretory products during transient vesicle fusion
de Toledo, G. A., Fernández-Chacón, R., & Fernández, J. M. (1993) · Nature · doi:10.1038/363554a0 · Cited by 587
A Novel Function for SMN, the Spinal Muscular Atrophy Disease Gene Product, in Pre-mRNA Splicing
Pellizzoni, L., Kataoka, N., Charroux, B., & Dreyfuss, G. (1998) · Cell · doi:10.1016/s0092-8674(00)81632-3 · Cited by 558
Kislinger, T., Cox, B., Kannan, A., Chung, C., Hu, P., Ignatchenko, A., Scott, M. S., Gramolini, A. O., Morris, Q., Hallett, M. T., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.044 · Cited by 482
Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy.
Pearn, J. (1978) · Journal of Medical Genetics · doi:10.1136/jmg.15.6.409 · Cited by 472
Farwell, K. D., Shahmirzadi, L., El-Khechen, D., Powis, Z., Chao, E. C., Tippin Davis, B., Baxter, R. M., Zeng, W., Mroske, C., Parra, M. C., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.154 · Cited by 470
Differential expression of synaptic vesicle protein 2 (SV2) isoforms
Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440
Chen, M.-K., Mecca, A. P., Naganawa, M., Finnema, S. J., Toyonaga, T., Lin, S.-F., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J. W., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1836 · Cited by 431
Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)
Crowder, K. M., Gunther, J. M., Jones, T. A., Hale, B. D., Zhang, H. Z., Peterson, M. R., Scheller, R. H., Chavkin, C., & Bajjalieh, S. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.15268 · Cited by 415
The architecture of active zone material at the frog's neuromuscular junction
Harlow, M. L., Ress, D., Stoschek, A., Marshall, R. M., & McMahan, U. J. (2001) · Nature · doi:10.1038/35054000 · Cited by 388
SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter Release
Janz, R., Goda, Y., Geppert, M., Missler, M., & Südhof, T. C. (1999) · Neuron · doi:10.1016/s0896-6273(00)81046-6 · Cited by 367
Rapid Reuse of Readily Releasable Pool Vesicles at Hippocampal Synapses
Pyle, J. L., Kavalali, E. T., Piedras-Rentería, E. S., & Tsien, R. W. (2000) · Neuron · doi:10.1016/s0896-6273(00)00098-2 · Cited by 345
Gorter, J. A., van Vliet, E. A., Aronica, E., Breit, T., Rauwerda, H., Lopes da Silva, F. H., & Wadman, W. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2766-06.2006 · Cited by 316
Dopamine neurons release transmitter via a flickering fusion pore
Staal, R. G. W., Mosharov, E. V., & Sulzer, D. (2004) · Nature Neuroscience · doi:10.1038/nn1205 · Cited by 308
The synaptic vesicle protein SV2 is a novel type of transmembrane transporter
Feany, M. B., Lee, S., Edwards, R. H., & Buckley, K. M. (1992) · Cell · doi:10.1016/0092-8674(92)90319-8 · Cited by 260
The DNA sequence and biological annotation of human chromosome 1
Gregory, S. G., Barlow, K. F., McLay, K. E., Kaul, R., Swarbreck, D., Dunham, A., Scott, C. E., Howe, K. L., Woodfine, K., Spencer, C. C. A., et al. (2006) · Nature · doi:10.1038/nature04727 · Cited by 257
SV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial Transporters
Bajjalieh, S. M., Peterson, K., Shinghal, R., & Scheller, R. H. (1992) · Science · doi:10.1126/science.1519064 · Cited by 256
Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach
Bereczki, E., Branca, R. M., Francis, P. T., Pereira, J. B., Baek, J.-H., Hortobágyi, T., Winblad, B., Ballard, C., Lehtiö, J., & Aarsland, D. (2018) · Brain · doi:10.1093/brain/awx352 · Cited by 220
A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse
Dwoskin, L. P., & Crooks, P. A. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00899-1 · Cited by 219
Cumbo, E., & Ligori, L. D. (2010) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2010.01.015 · Cited by 216
Synaptic vesicle membrane proteins interact to form a multimeric complex.
Bennett, M. K., Calakos, N., Kreiner, T., & Scheller, R. H. (1992) · The Journal of cell biology · doi:10.1083/jcb.116.3.761 · Cited by 216
Janz, R., & Südhof, T. C. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00370-x · Cited by 213
SV2 modulates the size of the readily releasable pool of secretory vesicles
Xu, T., & Bajjalieh, S. M. (2001) · Nature Cell Biology · doi:10.1038/35087000 · Cited by 212
Synaptic vesicle protein 2 enhances release probability at quiescent synapses
Custer, K. L., Austin, N. S., Sullivan, J. M., & Bajjalieh, S. M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2699-05.2006 · Cited by 211
Lohr, K. M., Bernstein, A. I., Stout, K. A., Dunn, A. R., Lazo, C. R., Alter, S. P., Wang, M., Li, Y., Fan, X., Hess, E. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402134111 · Cited by 209
Self-citationGenic insights from integrated human proteomics in GeneCards
Fishilevich, S., Zimmerman, S., Kohn, A., Iny Stein, T., Olender, T., Kolker, E., Safran, M., & Lancet, D. (2016) · Database · doi:10.1093/database/baw030 · Cited by 197
Dopamine and Glutamate in Huntington's Disease: A Balancing Act
André, V. M., Cepeda, C., & Levine, M. S. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00134.x · Cited by 189
Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
Kenney, C., Hunter, C., & Jankovic, J. (2007) · Movement Disorders · doi:10.1002/mds.21222 · Cited by 187
Mutch, S. A., Kensel-Hammes, P., Gadd, J. C., Fujimoto, B. S., Allen, R. W., Schiro, P. G., Lorenz, R. M., Kuyper, C. L., Kuo, J. S., Bajjalieh, S. M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3805-10.2011 · Cited by 185
Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond
Löscher, W., Gillard, M., Sands, Z. A., Kaminski, R. M., & Klitgaard, H. (2016) · CNS Drugs · doi:10.1007/s40263-016-0384-x · Cited by 184
SV2 Renders Primed Synaptic Vesicles Competent for Ca2+-Induced Exocytosis
Chang, W.-P., & Südhof, T. C. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4521-08.2009 · Cited by 176
Cotrafficking of SV2 and synaptotagmin at the synapse
Yao, J., Nowack, A., Kensel-Hammes, P., Gardner, R. G., & Bajjalieh, S. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4781-09.2010 · Cited by 164
Altered Intracellular Ca2+Homeostasis in Nerve Terminals of Severe Spinal Muscular Atrophy Mice
Ruiz, R., Casañas, J. J., Torres-Benito, L., Cano, R., & Tabares, L. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4496-09.2010 · Cited by 164
Rummel, A., Häfner, K., Mahrhold, S., Darashchonak, N., Holt, M., Jahn, R., Beermann, S., Karnath, T., Bigalke, H., & Binz, T. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06298.x · Cited by 162
Whole-Body Lifetime Occupational Lead Exposure and Risk of Parkinson’s Disease
Coon, S., Stark, A., Peterson, E., Gloi, A., Kortsha, G., Pounds, J., Chettle, D., & Gorell, J. (2006) · Environmental Health Perspectives · doi:10.1289/ehp.9102 · Cited by 161
Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer’s disease brains
Sze, C.-I., Bi, H., Kleinschmidt-DeMasters, B. K., Filley, C. M., & Martin, L. J. (2000) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(00)00285-9 · Cited by 161
Robinson, J. L., Molina-Porcel, L., Corrada, M. M., Raible, K., Lee, E. B., Lee, V. M.-Y., Kawas, C. H., & Trojanowski, J. Q. (2014) · Brain · doi:10.1093/brain/awu190 · Cited by 157
Glycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype F
Fu, Z., Chen, C., Barbieri, J. T., Kim, J.-J. P., & Baldwin, M. R. (2009) · Biochemistry · doi:10.1021/bi9002138 · Cited by 149
Gillard, M., Chatelain, P., & Fuks, B. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.022 · Cited by 148
Laminin Degradation by Plasmin Regulates Long-Term Potentiation
Nakagami, Y., Abe, K., Nishiyama, N., & Matsuki, N. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-05-02003.2000 · Cited by 145
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
Jankovic, J., & Clarence-Smith, K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.149 · Cited by 145
Schivell, A. E., Batchelor, R. H., & Bajjalieh, S. M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.44.27770 · Cited by 145
SV2 Mediates Entry of Tetanus Neurotoxin into Central Neurons
Yeh, F. L., Dong, M., Yao, J., Tepp, W. H., Lin, G., Johnson, E. A., & Chapman, E. R. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001207 · Cited by 142
SV2 Acts via Presynaptic Calcium to Regulate Neurotransmitter Release
Wan, Q.-F., Zhou, Z., Thakur, P., Vila, A., Sherry, D. M., Janz, R., & Heidelberger, R. (2010) · Neuron · doi:10.1016/j.neuron.2010.05.010 · Cited by 138
Dunn, A. R., Stout, K. A., Ozawa, M., Lohr, K. M., Hoffman, C. A., Bernstein, A. I., Li, Y., Wang, M., Sgobio, C., Sastry, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616892114 · Cited by 138
Self-citationVan Vliet, E. A., Aronica, E., Redeker, S., Boer, K., & Gorter, J. A. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2008.01727.x · Cited by 135
The Mitochondrial and Autosomal Mutation Landscapes of Prostate Cancer
Lindberg, J., Mills, I. G., Klevebring, D., Liu, W., Neiman, M., Xu, J., Wikström, P., Wiklund, P. N., Wiklund, F. E., Egevad, L., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.11.053 · Cited by 133
Chin, J., & Scharfman, H. E. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2012.11.040 · Cited by 132
Botulinum Neurotoxin D Uses Synaptic Vesicle Protein SV2 and Gangliosides as Receptors
Peng, L., Tepp, W. H., Johnson, E. A., & Dong, M. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002008 · Cited by 131
Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome
Jankovic, J., Glaze, D. G., & Frost, J. D. (1984) · Neurology · doi:10.1212/wnl.34.5.688 · Cited by 129
Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission
Yang, X., Weisenfeld, A., & Rothman, S. M. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2006.01132.x · Cited by 128
von Rosenstiel, P. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.004 · Cited by 125
The Choline Transporter Resurfaces: New Roles for Synaptic Vesicles?
Ferguson, S. M. (2004) · Molecular Interventions · doi:10.1124/mi.4.1.22 · Cited by 125
Chakkalakal, J. V., Nishimune, H., Ruas, J. L., Spiegelman, B. M., & Sanes, J. R. (2010) · Development · doi:10.1242/dev.053348 · Cited by 124
Zebrafish survival motor neuron mutants exhibit presynaptic neuromuscular junction defects
Boon, K.-L., Xiao, S., McWhorter, M. L., Donn, T. M., Wolf-Saxon, E. R., Bohnsack, M. T., Moens, C. B., & Beattie, C. E. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp310 · Cited by 121
N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A
Yao, G., Zhang, S., Mahrhold, S., Lam, K. H., Stern, D., Bagramyan, K. A., Perry, K., Kalkum, M., Rummel, A., Dong, M., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3245 · Cited by 118
Kaminski, R. M., Gillard, M., Leclercq, K., Hanon, E., Lorent, G., Dassesse, D., Matagne, A., & Klitgaard, H. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02089.x · Cited by 116
Von Kriegstein, K., Schmitz, F., Link, E., & Südhof, T. C. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00542.x · Cited by 113
Lobeline Attenuates d-Methamphetamine Self-Administration in Rats
Harrod, S. B., Dwoskin, L. P., Crooks, P. A., Klebaur, J. E., & Bardo, M. T. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29365-4 · Cited by 111
The SV2 Protein of Synaptic Vesicles Is a Keratan Sulfate Proteoglycan
Scranton, T. W., Iwata, M., & Carlson, S. S. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03535.x · Cited by 107
Epileptic Seizures in Alzheimer Disease: A Review
Horváth, A., Szűcs, A., Barcs, G., Noebels, J. L., & Kamondi, A. (2016) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000134 · Cited by 107
SV2A and SV2C contain a unique synaptotagmin-binding site
Schivell, A. E., Mochida, S., Kensel-Hammes, P., Custer, K. L., & Bajjalieh, S. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.12.011 · Cited by 102
Wood, M. D., & Gillard, M. (2017) · Epilepsia · doi:10.1111/epi.13638 · Cited by 101
SV2B Regulates Synaptotagmin 1 by Direct Interaction
Lazzell, D. R., Belizaire, R., Thakur, P., Sherry, D. M., & Janz, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407502200 · Cited by 100
Control of neurotransmitter release by an internal gel matrix in synaptic vesicles
Reigada, D., Díez-Pérez, I., Gorostiza, P., Verdaguer, A., Gómez de Aranda, I., Pineda, O., Vilarrasa, J., Marsal, J., Blasi, J., Aleu, J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336914100 · Cited by 98
Tetrabenazine Treatment in Movement Disorders
Paleacu, D., Giladi, N., Moore, O., Stern, A., Honigman, S., & Badarny, S. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000136892.24629.96 · Cited by 98
Pharmacology of Lobeline, A Nicotinic Receptor Ligand
Damaj, M. I., Patrick, G. S., Creasy, K. R., & Martin, B. R. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36807-7 · Cited by 96
Synaptic Vesicle Protein 2, A New Neuroendocrine Cell Marker
Portela‐Gomes, G. M., Lukinius, A., & Grimelius, L. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64645-7 · Cited by 90
Madeo, M., Kovács, A., & Pearce, D. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.c114.584516 · Cited by 83
Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A
Nowack, A., Malarkey, E. B., Yao, J., Bleckert, A., Hill, J., & Bajjalieh, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029560 · Cited by 81
Analysis of the DNA sequence and duplication history of human chromosome 15
Zody, M. C., Garber, M. G., Sharpe, T., Young, S., Rowen, L., O'Neill, K., Whittaker, C. A., Kamal, M., Chang, J. L., Cuomo, C. A., et al. (2006) · Nature · doi:10.1038/nature04601 · Cited by 78
A genetic basis for the variable effect of smoking/nicotine on Parkinson’s disease
Hill-Burns, E. M., Singh, N., Ganguly, P., Hamza, T. H., Montimurro, J. S., Kay, D. M., Yearout, D., Sheehan, P., Frodey, K., McLear, J. A., et al. (2012) · The Pharmacogenomics Journal · doi:10.1038/tpj.2012.38 · Cited by 74
Feng, G., Xiao, F., Lü, Y., Huang, Z., Yuan, J., Xiao, Z., Xi, Z., & Wang, X. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9288-2 · Cited by 74
Seizures and dementia in the elderly: Nationwide Inpatient Sample 1999–2008
Sherzai, D., Losey, T. E., Vega, S., & Sherzai, A. Z. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.04.015 · Cited by 72
Zhang, N., Gordon, S. L., Fritsch, M. J., Esoof, N., Campbell, D. G., Gourlay, R., Velupillai, S., Macartney, T., Peggie, M., van Aalten, D. M. F., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.4248-14.2015 · Cited by 72
Siwek, M. E., Müller, R., Henseler, C., Trog, A., Lundt, A., Wormuth, C., Broich, K., Ehninger, D., Weiergräber, M., & Papazoglou, A. (2015) · Neural Plasticity · doi:10.1155/2015/781731 · Cited by 71
Functional analysis of neurotransmission at β2‐laminin deficient terminals
Knight, D., Tolley, L. K., Kim, D. K., Lavidis, N. A., & Noakes, P. G. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2002.030924 · Cited by 68
Levetiracetam: the first SV2A ligand for the treatment of epilepsy
Klitgaard, H., & Verdru, P. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.11.1537 · Cited by 68
Helmstaedter, C., & Witt, J. (2010) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2010.02.011 · Cited by 66
Sola, I., Aso, E., Frattini, D., López-González, I., Espargaró, A., Sabaté, R., Di Pietro, O., Luque, F. J., Clos, M. V., Ferrer, I., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00624 · Cited by 66
Finnema, S. J., Rossano, S., Naganawa, M., Henry, S., Gao, H., Pracitto, R., Maguire, R. P., Mercier, J., Kervyn, S., Nicolas, J., et al. (2019) · Epilepsia · doi:10.1111/epi.14701 · Cited by 65
Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma
de Groot, M., Aronica, E., Heimans, J. J., & Reijneveld, J. C. (2011) · Neurology · doi:10.1212/wnl.0b013e318228c110 · Cited by 64
Dardou, D., Dassesse, D., Cuvelier, L., Deprez, T., Ryck, M. D., & Schiffmann, S. N. (2010) · Brain Research · doi:10.1016/j.brainres.2010.09.063 · Cited by 63
Subramaniam, S., & Snyder, S. H. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.025 · Cited by 63
Large Structural Change in Isolated Synaptic Vesicles upon Loading with Neurotransmitter
Budzinski, K. L., Allen, R. W., Fujimoto, B. S., Kensel-Hammes, P., Belnap, D. M., Bajjalieh, S., & Chiu, D. T. (2009) · Biophysical Journal · doi:10.1016/j.bpj.2009.08.032 · Cited by 62
Devi, L., & Ohno, M. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.02.001 · Cited by 61
Binding characteristics of [3H]ucb 30889 to levetiracetam binding sites in rat brain
Gillard, M. R., Fuks, B., Michel, P., Vertongen, P., Massingham, R., & Chatelain, P. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.08.032 · Cited by 61
Bennett, B. A., Matagne, A., Michel, P., Leonard, M., Cornet, M., Meeus, M.-A., & Toublanc, N. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2006.11.014 · Cited by 61
Measuring brain synaptic vesicle protein 2A with positron emission tomography and [ 18 F]UCB‐H
Bahri, M. A., Plenevaux, A., Aerts, J., Bastin, C., Becker, G., Mercier, J., Valade, A., Buchanan, T., Mestdagh, N., Ledoux, D., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.08.004 · Cited by 61
SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment
Iezzi, M., Theander, S., Janz, R., Loze, C., & Wollheim, C. B. (2005) · Journal of Cell Science · doi:10.1242/jcs.02658 · Cited by 60
A Mitochondrial Role of SV2a Protein in Aging and Alzheimer’s Disease: Studies with Levetiracetam
Stockburger, C., Miano, D., Baeumlisberger, M., Pallas, T., Arrey, T. N., Karas, M., Friedland, K., & Müller, W. E. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150687 · Cited by 60
Ping, Y., Hahm, E.-T., Waro, G., Song, Q., Vo-Ba, D.-A., Licursi, A., Bao, H., Ganoe, L., Finch, K., & Tsunoda, S. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005025 · Cited by 59
Association of Botulinum Neurotoxin Serotypes A and B with Synaptic Vesicle Protein Complexes
Baldwin, M. R., & Barbieri, J. T. (2007) · Biochemistry · doi:10.1021/bi602396x · Cited by 59
Tetrabenazine for the Treatment of Tardive Dyskinesia
Leung, J. G., & Breden, E. L. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p312 · Cited by 58
Serajee, F., & Huq, A. M. (2015) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2015.02.011 · Cited by 57
Proton electrochemical gradient: Driving and regulating neurotransmitter uptake
Farsi, Z., Jahn, R., & Woehler, A. (2017) · BioEssays · doi:10.1002/bies.201600240 · Cited by 56
Valbenazine granted breakthrough drug status for treating tardive dyskinesia
Müller, T. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1029573 · Cited by 55
Vesicular Integrity in Parkinson’s Disease
Alter, S. P., Lenzi, G. M., Bernstein, A. I., & Miller, G. W. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0362-3 · Cited by 55
Self-citationMorgans, C. W., Kensel-Hammes, P., Hurley, J. B., Burton, K., Idzerda, R., McKnight, G. S., & Bajjalieh, S. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005230 · Cited by 55
Is History of Depression a Contraindication to Treatment With Tetrabenazine?
Kenney, C., Hunter, C., Mejia, N., & Jankovic, J. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000228369.25593.35 · Cited by 55
Generation and Characterization of a genetic zebrafish model of SMA carrying the human SMN2gene
Hao, L. T., Burghes, A. H. M., & Beattie, C. E. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-24 · Cited by 54
Tejero, R., López-Manzaneda, M., Arumugam, S., & Tabares, L. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw297 · Cited by 53
Son, Y.-J., Scranton, T. W., Sunderland, W. J., Baek, S. J., Miner, J. H., Sanes, J. R., & Carlson, S. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.451 · Cited by 52
Redenšek, S., Flisar, D., Kojović, M., Kramberger, M. G., Georgiev, D., Pirtošek, Z., Trošt, M., & Dolžan, V. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00008 · Cited by 52
Gingrich, J. A., Andersen, P. H., Tiberi, M., Mestikawy, S. E., Jorgensen, P. N., Fremeau, R. T., & Caron, M. G. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)80917-6 · Cited by 51
Chan, J., Jones, N. C., Bush, A. I., O'Brien, T. J., & Kwan, P. (2015) · Epilepsia · doi:10.1111/epi.12993 · Cited by 50
Brivaracetam augments short‐term depression and slows vesicle recycling
Yang, X., Bognar, J., He, T., Mohammed, M., Niespodziany, I., Wolff, C., Esguerra, M., Rothman, S. M., & Dubinsky, J. M. (2015) · Epilepsia · doi:10.1111/epi.13223 · Cited by 47
Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E
Mahrhold, S., Strotmeier, J., Garcia-Rodriguez, C., Lou, J., Marks, J. D., Rummel, A., & Binz, T. (2013) · Biochemical Journal · doi:10.1042/bj20130391 · Cited by 47
No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy
Lynch, J. M., Tate, S. K., Kinirons, P., Weale, M. E., Cavalleri, G. L., Depondt, C., Murphy, K. D., O’Rourke, D., Doherty, C. P., Shianna, K. V., et al. (2008) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.09.003 · Cited by 46
von Kriegstein, K., & Schmitz, F. (2003) · Cell and Tissue Research · doi:10.1007/s00441-002-0674-0 · Cited by 44
Harlow, M. L., Szule, J. A., Xu, J., Jung, J. H., Marshall, R. M., & McMahan, U. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069410 · Cited by 44
Dale, J. M., Shen, H., Barry, D. M., Garcia, V. B., Rose, F. F., Lorson, C. L., & Garcia, M. L. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0848-5 · Cited by 44
Douaud, M., Feve, K., Pituello, F., Gourichon, D., Boitard, S., Leguern, E., Coquerelle, G., Vieaud, A., Batini, C., Naquet, R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026932 · Cited by 43
Ziyatdinova, S., Rönnbäck, A., Gurevicius, K., Miszczuk, D., Graff, C., Winblad, B., Pitkänen, A., & Tanila, H. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160129095508 · Cited by 43
Wu, T., Chen, C.-C., Chen, T.-C., Tseng, Y.-F., Chiang, C.-B., Hung, C., & Liou, H. (2009) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2009.08.026 · Cited by 42
Ohno, Y., Ishihara, S., Terada, R., Kikuta, M., Sofue, N., Kawai, Y., Serikawa, T., & Sasa, M. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.09.035 · Cited by 41
Structure and Metabolism of Proteoglycans and Glycosaminoglycans
Silbert, J. E. (1982) · Journal of Investigative Dermatology · doi:10.1038/jid.1982.7 · Cited by 41
A New SV2A Ligand for Epilepsy
Rogawski, M. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.057 · Cited by 40
Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis
Ohno, Y., & Tokudome, K. (2017) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527316666170404115027 · Cited by 40
A role for Sv2c in basal ganglia functions
Dardou, D., Monlezun, S., Foerch, P., Courade, J., Cuvelier, L., Ryck, M. D., & Schiffmann, S. N. (2013) · Brain Research · doi:10.1016/j.brainres.2013.02.041 · Cited by 38
Nicholls, D. G., Brand, M. D., & Gerencser, A. A. (2014) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-014-9573-9 · Cited by 38
Influence of Genetic, Biological and Pharmacological Factors on Levodopa Dose in Parkinson’s Disease
Altmann, V., Schuh, A. F. S., Rieck, M., Callegari-Jacques, S. M., Rieder, C. R. D. M., & Hutz, M. H. (2016) · Pharmacogenomics · doi:10.2217/pgs.15.183 · Cited by 38
Chand, K. K., Lee, K. M., Schenning, M. P., Lavidis, N. A., & Noakes, P. G. (2015) · The Journal of Physiology · doi:10.1113/jphysiol.2014.284133 · Cited by 37
Wood, M. D., Sands, Z. A., Vandenplas, C., & Gillard, M. (2018) · Epilepsia · doi:10.1111/epi.14532 · Cited by 37
Vogl, C., Tanifuji, S., Danis, B., Daniels, V., Foerch, P., Wolff, C., Whalley, B. J., Mochida, S., & Stephens, G. J. (2015) · European Journal of Neuroscience · doi:10.1111/ejn.12799 · Cited by 35
The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats
Beckmann, J. S., Denehy, E. D., Zheng, G., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2488-9 · Cited by 34
Levetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking
García‐Pérez, E., Mahfooz, K., Covita, J., Zandueta, A., & Wesseling, J. F. (2015) · Epilepsia · doi:10.1111/epi.12930 · Cited by 34
Bümming, P., Nilsson, O., Ahlman, H., Welbencer, A., Andersson, M. K., Sjölund, K., & Nilsson, B. (2007) · Endocrine Related Cancer · doi:10.1677/erc-06-0014 · Cited by 34
Detrait, E., Maurice, T., Hanon, É., Leclercq, K., & Lamberty, Y. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.06.013 · Cited by 32
Jakobsen, A.-M. L., Ahlman, H., Wängberg, B., Kölby, L., Bengtsson, M., & Nilsson, O. (2001) · The Journal of Pathology · doi:10.1002/path.1002 · Cited by 31
Mahrhold, S., Bergström, T. B., Stern, D., Dorner, B. G., Åstot, C., & Rummel, A. (2016) · Biochemical Journal · doi:10.1042/bcj20160439 · Cited by 31
Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics
Davies, J. R., Liu, S. M., & Acharya, K. R. (2018) · Toxins · doi:10.3390/toxins10100421 · Cited by 31
Structure and Metabolism of Proteoglycans and Glycosaminoglycans.
Silbert, J. E. (1982) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12545094 · Cited by 31
Association of botulinum neurotoxins with synaptic vesicle protein complexes
Baldwin, M. R., & Barbieri, J. T. (2009) · Toxicon · doi:10.1016/j.toxicon.2009.01.040 · Cited by 30
Effects of methylphenidate: the cellular point of view
Bartl, J., Link, P., Schlosser, C., Gerlach, M., Schmitt, A., Walitza, S., Riederer, P., & Grünblatt, E. (2010) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-010-0039-6 · Cited by 29
Dimatelis, J. J., Russell, V. A., Stein, D. J., & Daniels, W. M. U. (2012) · Metabolic Brain Disease · doi:10.1007/s11011-012-9288-8 · Cited by 29
Wang, L., Shi, J., Wu, G., Zhou, F., & Hong, Z. Y. (2014) · Epilepsy Research · doi:10.1016/j.eplepsyres.2014.07.005 · Cited by 28
Importance of Vesicle Proteins in the Diagnosis and Treatment of Neuroendocrine Tumors
Nilsson, O., Jakobsen, A.-M. L., Kölby, L., Bernhardt, P., Forssell-Aronsson, E. B., & Ahlman, H. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1294.032 · Cited by 27
Beckmann, J. S., Siripurapu, K. B., Nickell, J. R., Horton, D. B., Denehy, E. D., Vartak, A. P., Crooks, P. A., Dwoskin, L. P., & Bardo, M. T. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.172742 · Cited by 25
Immunochemical analysis of the expression of SV2C in mouse, macaque and human brain
Dunn, A. R., Hoffman, C. A., Stout, K. A., Ozawa, M., Dhamsania, R. K., & Miller, G. W. (2017) · Brain Research · doi:10.1016/j.brainres.2017.12.029 · Cited by 25
Self-citationGenotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE Study
Ramsey, T. L., Liu, Q., Massey, B. W., & Brennan, M. D. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.07.008 · Cited by 22
Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line
Schmitt, M., Dehay, B., Bézard, E., & Garcia-Ladona, F. J. (2015) · Synapse · doi:10.1002/syn.21881 · Cited by 22
Heese, K., Nagai, Y., & Sawada, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5932 · Cited by 21
Positive impact of levetiracetam on emotional learning and memory in naive mice
Celikyurt, I. K., Ulak, G., Mutlu, O., Akar, F., Mülayim, S., Erden, F., & Komsuoğlu, S. Ş. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.11.003 · Cited by 20
Higuera‐Matas, A., Montoya, G. L., Coria, S. M., Miguéns, M., García-Lecumberri, C., & Ambrosio, E. (2011) · Current Neuropharmacology · doi:10.2174/157015911795017290 · Cited by 20
Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures
Schoemaker, R. C., Wade, J. R., D’Souza, J., & Stockis, A. (2017) · Epilepsy Research · doi:10.1016/j.eplepsyres.2017.09.014 · Cited by 18
Contreras‐García, I. J., Pichardo‐Macías, L. A., Santana‐Gomez, C., Sánchez-Huerta, K., Ramírez-Hernández, R., Gómez‐González, B., Rocha, L., & Mendoza‐Torreblanca, J. G. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.08.023 · Cited by 18
Sugata, S., Hanaya, R., Kumafuji, K., Tokudome, M., Serikawa, T., Kurisu, K., Arita, K., & Sasa, M. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.05.017 · Cited by 17
Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C
Peng, C., Zhu, G., Liu, X., & Li, H. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0230-x · Cited by 16
Anxiety-like features and spatial memory problems as a consequence of hippocampal SV2A expression
Navacerrada, M. E. S., Bartholomé, O., den Ackerveken, P. V., Ferrara, A., Rogister, B., Plenevaux, A., & Tirelli, E. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217882 · Cited by 15
Rare protein sequence variation in SV2A gene does not affect response to levetiracetam
Dibbens, L. M., Hodgson, B. L., Helbig, K. L., Oliver, K. L., Mulley, J. C., Berkovic, S. F., & Scheffer, I. E. (2012) · Epilepsy Research · doi:10.1016/j.eplepsyres.2012.04.007 · Cited by 13
Navacerrada, M. E. S., Becker, G., Bahri, M. A., Seret, A., Mestdagh, N., Mercier, J., Miévis, F., Giacomelli, F., Lemaire, C. F., Salmon, É., et al. (2019) · Molecules · doi:10.3390/molecules24091705 · Cited by 13
Harada, S., Tanaka, S., Takahashi, Y., Matsumura, H., Shimamoto, C., Nakano, T., Kuwabara, H., Sawabe, Y., & Nakahari, T. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.037 · Cited by 11
Lead exposure inhibits expression of SV2C through NRSF
Yang, M., Li, Y., Hu, L., Luo, D., Zhang, Y., Xiao, X., Li, G., Zhang, L., & Zhu, G. (2018) · Toxicology · doi:10.1016/j.tox.2018.02.009 · Cited by 11
Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats
Shi, J., Zhou, F., Wang, L., & Wu, G. (2015) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-015-1496-0 · Cited by 10
Chang, S., He, H., Shen, L. F., & Wan, H. (2015) · Biopolymers · doi:10.1002/bip.22682 · Cited by 9
Research works printed but not linked: 2
- Damaj M. I., 1997, J. Pharmacol. Exp. Ther., 282, 410
- Harrod S. B., 2001, J. Pharmacol. Exp. Ther., 298, 172
Cited by
Levetiracetam Mechanisms of Action: From Molecules to Systems
Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A. (2022) · Pharmaceuticals · doi:10.3390/ph15040475 · Cited by 131
“[8,91,119]; then, LEV would act as improver of synaptic vesicle exocytosis.”
BackgroundEmerging roles of N-linked glycosylation in brain physiology and disorders
Conroy, L. R., Hawkinson, T. R., Young, L. E. A., Gentry, M. S., & Sun, R. C. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.09.006 · Cited by 109
Kamondi, A., Grigg-Damberger, M. M., Löscher, W., Tanila, H., & Horvath, A. A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00932-4 · Cited by 127
“SV2B has also been implicated in the pathophysiology of AD 169 .”
Emerging Roles of the Human Solute Carrier 22 Family
Yee, S. W., & Giacomini, K. M. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000702 · Cited by 71
Bortolami, M., Rocco, D., Messore, A., Santo, R. D., Costi, R., Madia, V. N., Scipione, L., & Pandolfi, F. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1874344 · Cited by 73
Metadata
- Authors
- Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W.
- Affiliations
- Northwestern University (US)
- Jackson Laboratory (US)
- Emory University (US)
- Columbia University (US)
- Corresponding author
- Stout, Kristen A.
- Miller, Gary W.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-08-08
- Volume
- 10
- Issue
- 9
- Pages
- 3927-3938
- ISSN
- 1948-7193 (ISSN-L)
- PMC
- PMC11562936
- OpenAlex
- W2967602434
- Cited by
- 112
- References
- 167
- Citations by year
- 2026: 16 · 2025: 21 · 2024: 23 · 2023: 19 · 2022: 13 · 2021: 13 · 2020: 5 · 2019: 1
- FWCI
- 0.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- The Mouseion at the JAXlibrary (Jackson Laboratory) (submittedVersion)
- Funders
- U.S. Department of Health and Human Services (ES012870, ES023839, NS089242, AG058396, DA037652)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Keywords
- SV2A, SV2B, SV2C, neurotransmitter release, presynaptic terminals, secretory vesicles, levetiracetam, botulinum toxin, Alzheimer's disease, Parkinson's disease, neuronal excitability, paralogs
- MeSH terms
- Animals, Humans, Membrane Glycoproteins, Nerve Tissue Proteins, Nervous System Diseases, Synaptic Vesicles, Protein Transport
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.